Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: Systematic review and economic evaluation

Health Technology Assessment

Volumn 20, Issue 35, 2016, Pages

  Stevenson, Matt ^a   Archer, Rachel ^a   Tosh, Jon ^a   Simpson, Emma ^a   Everson Hock, Emma ^a   Stevens, John ^a   Hernandez Alava, Monica ^a   Paisley, Suzy ^a   Dickinson, Kath ^a   Scott, David ^b   Young, Adam ^c   Wailoo, Allan ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c WEST HERTFORDSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; TOFACITINIB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADVERSE OUTCOME; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DAS28; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; ECONOMIC EVALUATION; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INCIDENCE; INJECTION SITE REACTION; MORTALITY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PNEUMONIA; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS; VISUAL ANALOG SCALE; COST BENEFIT ANALYSIS; NETWORK META-ANALYSIS;

ABATACEPT; ADALIMUMAB; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CERTOLIZUMAB PEGOL; COST-BENEFIT ANALYSIS; ETANERCEPT; HUMANS; INFLIXIMAB; METHOTREXATE; NETWORK META-ANALYSIS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84966549646     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta20350     Document Type: Review

References (325)

1. Scott DL, Steer S. The course of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:943-67. http://dx.doi.org/10.1016/j.berh.2007.05.006
2. Pincus T, Fuchs HA, Callahan LF, Nance EP Jr, Kaye JJ. Early radiographic joint space narrowing and erosion and later malalignment in rheumatoid arthritis: a longitudinal analysis. J Rheumatol 1998;25:636-40.
3. Drossaers-Bakker KW, Kroon HM, Zwinderman AH, Breedveld FC, Hazes JM. Radiographic damage of large joints in long-term rheumatoid arthritis and its relation to function. Rheumatology 2000;39:998-1003. http://dx.doi.org/10.1093/rheumatology/39.9.998
4. Allaire S, Wolfe F, Niu J, LaValley MP, Zhang B, Reisine S. Current risk factors for work disability associated with rheumatoid arthritis: recent data from a US national cohort. Arthritis Rheum 2009;61:321-8. http://dx.doi.org/10.1002/art.24281
5. Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:871-83. http://dx.doi.org/10.1016/j.berh.2007.05.003
6. Dadoun S, Zeboulon-Ktorza N, Combescure C, Elhai M, Rozenberg S, Gossec L, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 2013;80:29-33. http://dx.doi.org/10.1016/j.jbspin.2012.02.005
7. Meune C, Touze E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2009;48:1309-13. http://dx.doi.org/10.1093/rheumatology/kep252
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. http://dx.doi.org/10.1002/art.1780310302
9. National Collaborating Centre for Chronic Conditions (UK). Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults. London: Royal College of Physicians; 2009.
10. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45. http://dx.doi.org/10.1136/ard.2005.044354
11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8. http://dx.doi.org/10.1136/ard.2010.138461
12. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35. http://dx.doi.org/10.1002/art.1780380602
13. van Gestel AM, Prevoo ML, van Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40. http://dx.doi.org/10.1002/art.1780390105
14. Felson DT. Assessing the efficacy and safety of rheumatic disease treatments: obstacles and proposed solutions. Arthritis Rheum 2003;48:1781-7. http://dx.doi.org/10.1002/art.11087
15. Prevoo M, van’t Hof M, Kuper H, Van Leeuwen M, van de Putte L, van Riel P. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8. http://dx.doi.org/10.1002/art.1780380107
16. van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999;26:705-11.
17. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23:S14-18.
18. Symmons D, Turner G, Webb R, Asten P, Barrett EM, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002;41:793-800. http://dx.doi.org/10.1093/rheumatology/41.7.793
19. Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33:735-9. http://dx.doi.org/10.1093/rheumatology/33.8.735
20. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-6. http://dx.doi.org/10.1016/j.autrev.2004.09.002
21. Lugmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the management of rheumatoid arthritis (the first 2 years). Rheumatology 2006;45:1167-9. http://dx.doi.org/10.1093/rheumatology/kel215a
22. National Institute for Health and Care Excellence. Adalimumab, Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis; 2007. URL: www.nice.org.uk/guidance/TA130 (accessed 30 July 2013).
23. National Institute for Health and Care Excellence. Certolizumab Pegol for the Treatment of Rheumatoid Arthritis; 2010. URL: www.nice.org.uk/guidance/TA186 (accessed 2 August 2013).
24. National Institute for Health and Care Excellence. Golimumab for the Treatment of Rheumatoid Arthritis after the Failure of Previous Disease-Modifying Anti-Rheumatic Drugs; 2011. URL: www.nice.org.uk/guidance/TA225 (accessed 30 July 2013).
25. National Institute for Health and Care Excellence. Rheumatoid Arthritis (Methotrexate-Naïve)-Golimumab (Terminated Appraisal): Guidance; 2011. URL: www.nice.org.uk/guidance/TA224 (accessed 30 July 2013).
26. National Institute for Health and Care Excellence. Tocilizumab for the Treatment of Rheumatoid Arthritis (Rapid Review of Technology Appraisal Guidance 198). TA247; 2012. URL: www.nice.org.uk/guidance/ta247 (accessed 31 July 2013).
27. National Institute for Health and Care Excellence. Abatacept for Treating Rheumatoid Arthritis After the Failure of Conventional Disease-Modifying Anti-Rheumatic Drugs (Rapid Review of Technology Appraisal Guidance 234); 2013. URL: www.nice.org.uk/guidance/TA280 (accessed 2 August 2013).
28. National Institute for Health and Care Excellence. Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a TNF Inhibitor; 2010. URL: www.nice.org.uk/guidance/ta195 (accessed 2 August 2013).
29. School of Health and Related Research, University of Sheffield. NICE Protocol-Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for the Treatment of Rheumatoid Arthritis not Previously Treated with Disease-Modifying Anti-Rheumatic Drugs and After the Failure of Conventional Disease-Modifying Anti-Rheumatic Drugs Only (Review of Technology Appraisal Guidance 130, 186, 224, 234 and a Part Review of Technology Appraisal Guidance 225 and 247). Sheffield: University of Sheffield; 2012.
30. Joint Formulary Committee. British National Formulary. 64 ed. London: BMJ Group and Pharmaceutical Press; 2012.
31. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Were SR, Hedges Team. Optimal search strategies for retrieving scientifically strong studies of treatment from MEDLINE: analytical survey. BMJ 2005;330:1179. http://dx.doi.org/10.1136/bmj.38446.498542.8F
32. Montori VM, Wilczynski NL, Morgan D, Haynes RB. Optimal search strategies for retrieving systematic reviews from MEDLINE: analytical survey. BMJ 2005;330:68 http://dx.doi.org/10.1136/bmj.38336.804167.47
33. Wong SS, Wilczynski NL, Haynes RB. Optimal CINAHL search strategies for identifying therapy studies and review articles. J Nurs Scholarsh 2006;38:194-9. http://dx.doi.org/10.1111/j.1547-5069.2006.00100.x
34. Wilczynski NL, Haynes RB. EMBASE search strategies achieved high sensitivity and specificity for retrieving methodologically sound systematic reviews. J Clin Epidemiol 2007;60:29-33. http://dx.doi.org/10.1016/j.jclinepi.2006.04.001
35. Wong SS, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc 2006;94:41-7.
36. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for Studies. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). URL: www.cochrane-handbook.org (accessed 10 August 2011).
37. Golder S, Mcintosh HM, Duffy S, Glanville J. Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Info Libr J 2006;23:3-12. http://dx.doi.org/10.1111/j.1471-1842.2006.00634.x
38. National Institute for Health and Care Excellence. Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of Conventional Disease Modifying Anti-Rheumatic Drugs. TA234; 2011. URL: www.nice.org.uk/guidance/ta234 (accessed 5 July 2013).
39. Information Services, Canadian Agency for Drugs and Technologies in Health (CADTH). Grey Matters: A Practical Search Tool for Evidence-Based Medicine. Ottawa, ON: CADTH; 2013.
40. National Institute for Health and Care Excellence. Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Abatacept and Tocilizumab for the Treatment of Rheumatoid Arthritis (Review of TA Guidance 130, 186, 224, 234 and Part Review of TA Guidance 225 and 247) Final scope. 2012. URL: www.nice.org.uk/guidance/TA375/documents/rheumatoid-arthritisadalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-abatacept-and-tocilizumabreview-final-scope-2 (accessed 5 July 2013).
41. Electronic Medicines Compendium. Summary of Product Characteristics-Cimzia (Certolizumab); 2013. URL: www.medicines.org.uk/emc/medicine/22323/SPC/Cimzia+200+mg+solution+for +injection/(accessed 5 July 2013).
42. Electronic Medicines Compendium. Summary of Product Characteristics-Enbrel (Etanercept); 2012. URL: www.medicines.org.uk/emc/searchresults.aspx?term=Enbrel&searchtype=QuickSearch (accessed 5 July 2013).
43. Electronic Medicines Compendium. Summary of Product Characteristics-HUMIRA (Adalimumab); 2013. URL: www.medicines.org.uk/emc/medicine/21201/SPC/Humira+Pre-filled+Pen%2c+Prefilled+ Syringe+and+Vial/(accessed 5 July 2013).
44. Electronic Medicines Compendium. Summary of Product Characteristics-Orencia® (Abatacept); 2012. URL: www.medicines.org.uk/emc/medicine/27216/SPC/ORENCIA+125+mg+solution+for +injection+(pre-filled+syringe)/(accessed 5 July 2013).
45. Electronic Medicines Compendium. Summary of Product Characteristics-Remicade (Infliximab); 2013. URL: www.medicines.org.uk/emc/medicine/3236/SPC/Remicade+100mg+powder+for +concentrate+for+solution+for+infusion/(accessed 5 July 2013).
46. Electronic Medicines Compendium. Summary of Product Characteristics-Simponi (Golimumab); 2013. URL: www.medicines.org.uk/emc/medicine/23766/SPC/Simponi+50+mg+solution+for +injection/(accessed 5 July 2013).
47. Electronic Medicines Compendium. Summary of Product Characteristics. RoActemra (Tocilizumab); 2013. URL: www.medicines.org.uk/emc/medicine/22311/SPC/RoActemra+20mg+ml+Concentrate +for+Solution+for+Infusion/(accessed 5 July 2013).
48. Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Systematic Reviews in Health Care. York: University of York; 2009.
49. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. URL: http://handbook. cochrane.org/(accessed 2 August 2013).
50. Karsh J, Keystone EC, Haraoui B, Thorne JC, Pope JE, Bykerk VP, et al. Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design. J Rheumatol 2011;38:2095-104. http://dx.doi.org/10.3899/jrheum.110188
51. Thorlund K, Druyts E, Avina-Zubieta JA, Wu P, Mills EJ. Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Ann Rheum Dis 2012;72:1524-35. http://dx.doi.org/10.1136/annrheumdis-2012-201574
52. Dias S, Welton N, Sutton A, Ades A. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. London: NICE; 2011.
53. Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, Clair EW, et al. A randomised comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 2012;64:2824-35. http://dx.doi.org/10.1002/art.34498
54. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81. http://dx.doi.org/10.1016/S0140-6736(04)15640-7
55. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96. http://dx.doi.org/10.1136/ard.2008.105197
56. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double-blind, randomised, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 2006;33:37-44.
57. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50. http://dx.doi.org/10.1136/annrheumdis-2011-201282
58. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50. http://dx.doi.org/10.1016/S0140-6736(13)60250-0 59.
59. van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006;65:1478-83. http://dx.doi.org/10.1136/ard.2005.043299
60. van Riel PLCM, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 2008;67:1104-10. http://dx.doi.org/10.1136/ard.2006.068585
61. Russell AS, Wallenstein GV, Li T, Martin MC, MacLean R, Blaisdell B, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 2007;66:189-94. http://dx.doi.org/10.1136/ard.2006.057018
62. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomised trial. Ann Intern Med 2006;144:865-76. http://dx.doi.org/10.7326/0003-4819-144-12-200606200-00003
63. Kremer J, Russell AS, Westhovens R, Teng J, Rosenblatt L, Emery P. Sustained and clinically meaningful improvements in both day-and night-time aspects of HRQoL are observed with abatacept treatment in patients with rheumatoid arthritis (RA) and previous inadequate response to MTX: 5-year data from the AIM trial. Arthritis Rheum 2010;62:1836.
64. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953-63. http://dx.doi.org/10.1002/art.23397
65. Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011;70:1826-30. http://dx.doi.org/10.1136/ard.2010.139345
66. Fleischmann R, Schiff MH, Weinblatt ME, Maldonado MA, Massarotti EM, Yazici Y. Effects of subcutaneous abatacept or adalimumab on remission and associated changes in physical function and radiographic outcomes: one year results from the ample (abatacept versus adalimumab comparison in biologic-naive RA subjects with background methotrexate) trial. Arthritis Rheum 2012;64:S577.
67. Kim H-Y, Hsu P-N, Barba M, Sulaiman W, Robertson D, Vlahos B, et al. Randomised comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. Int J Rheum Dis 2012;15:188-96. http://dx.doi.org/10.1111/j.1756-185X.2011. 01680.x
68. Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, et al. Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskelet Disord 2013;14:13. http://dx.doi.org/10.1186/1471-2474-14-13
69. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumour necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45. http://dx.doi.org/10.1002/art.10697
70. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65:753-9. http://dx.doi.org/10.1136/ard.2005.044404
71. St Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomised, controlled trial. Arthritis Rheum 2004;50:3432-43. http://dx.doi.org/10.1002/art.20568
72. Conaghan P, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis 2013;72:1287-94. http://dx.doi.org/10.1136/annrheumdis-2012-201611
73. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomised, placebocontrolled study. Arthritis Rheum 2006;54:2807-16. http://dx.doi.org/10.1002/art.22070
74. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103. http://dx.doi.org/10.1136/ard.2007.080002
75. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9. http://dx.doi.org/10.1016/S0140-6736(99)05246-0
76. van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomised, placebo-controlled trial. Arthritis Rheum 2011;63:1782-92. http://dx.doi.org/10.1002/art.30372
77. Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan A-M, Walker D, et al. Effect of the early use of the anti-tumour necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthrit Care Res 2008;59:1467-74. http://dx.doi.org/10.1002/art.24106
78. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van ZD, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeST study): a randomised, controlled trial. Arthritis Rheum 2008;52:3381-90. http://dx.doi.org/10.1002/art.21405
79. Smolen J, Emery P, Ferraccioli G. Efficacy and safety of certolizumab pegol after incomplete response to DMARDS in RA patients with low moderate disease activity: results from certain, a phase IIIb study. Ann Rheum Dis 2011;70:S259. http://dx.doi.org/10.1136/annrheumdis-2013-204632
80. Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol 2008;18:252-62. http://dx.doi.org/10.3109/s10165-008-0045-0
81. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82. http://dx.doi.org/10.1016/S0140-6736(08)61000-4
82. Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomised study. Arthritis Rheum 2010;62:674-82. http://dx.doi.org/10.1002/art.27268
83. Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 2010;69:222-5. [Erratum appears in Ann Rheum Dis 201;70:1519.] http://dx.doi.org/10.1136/ard.2008.102509
84. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumour necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomised, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. http://dx.doi.org/10.1002/art.20217
85. deFilippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. Panminerva Med 2006;48:129-35.
86. Durez P, Nzeusseu TA, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis 2004;63:1069-74. http://dx.doi.org/10.1136/ard.2003.012914
87. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93. http://dx.doi.org/10.1056/NEJM200011303432201
88. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 2006;65:1357-62. http://dx.doi.org/10.1136/ard.2005.049650
89. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis 2009;68:1146-52. http://dx.doi.org/10.1136/ard.2007.087106
90. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumour necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomised, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83. http://dx.doi.org/10.1002/art.24638
91. Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis 2012;71:817-24. http://dx.doi.org/10.1136/ard. 2011.200317
92. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35. http://dx.doi.org/10.1136/ard.2009.116319
93. Soubrier M, Puechal X, Sibilia J, Mariette X, Meyer O, Combe B, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 2009;48:1429-34. http://dx.doi.org/10.1093/rheumatology/kep261
94. Detert J, Bastian H, Listing J, Weis A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50. http://dx.doi.org/10.1136/annrheumdis-2012-201612
95. Nam JL, Villeneuve E, Conaghan PG, Hensor E, Keen HI, Amarasena R, et al. A preliminary report of remission induction with two therapeutic strategies with infliximab or high dose intravenous steroids for the treatment of rheumatoid arthritis. Arthritis Rheum 2011;63(Suppl. 10):463.
96. Keystone EC, Wang MM, Layton M, Hollis S, McInnes IB, Study Team. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 2012;71:1630-5. [Erratum appears in Ann Rheum Dis 2012;71:2064.] http://dx.doi.org/10.1136/annrheumdis-2011-143578
97. Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomised trial. Mod Rheumatol 2010;20:531-8. http://dx.doi.org/10.3109/s10165-010-0324-4
98. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomised, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75. http://dx.doi.org/10.1002/art.23383
99. Kim H-Y, Lee S-K, Song YW, Yoo D-H, Koh E-M, Yoo B, et al. A randomised, double-blind, placebo-controlled, phase III study of the human anti-tumour necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. Int J Rheum Dis 2007;10:9-16.
100. Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomised controlled trial. J Rheumatol 2011;38:2169-71. http://dx.doi.org/10.3899/jrheum.110340
101. Lan J-L, Chou S-J, Chen D-Y, Chen Y-H, Hsieh T-Y, Young J. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomised, placebo-controlled study. J Formos Med Assoc 2004;103:618-23.
102. Machado D, Guzman R, Xavier R, Simon J, Ferdousi T, Pedersen R, et al. Combination Etanercept and Methotrexate Therapy Provides Better Outcomes Than Standard DMARD and Methotrexate Therapy in Rheumatoid Arthritis: Results From a Study in the Latin America Region. Presented at XVII Congress of Pan American League of Associations of Rheumatology (PANLAR); Punta Cana, Dominican Republic; 17-21 April 2012.
103. Mcinnes I, Lee JS, Wu W, Giles JT, Bathon JM, Salmon JE, et al. MEASURE: a translational, randomised, placebo (PBO)-controlled study to evaluate the effects of tocilizumab (TCZ) on parameters of lipids and inflammation. Ann Rheum Dis 2011;70:S73.
104. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomised, controlled trial. Ann Intern Med 1999;130:478-86. http://dx.doi.org/10.7326/0003-4819-130-6-199903160-00004
105. Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000;22:128-39. http://dx.doi.org/10.1016/S0149-2918(00) 87984-9
106. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanised anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9. http://dx.doi.org/10.1002/art.20303
107. Hørslev-Petersen K. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 2014;73:654-61. http://dx.doi.org/10.1136/annrheumdis-2012-202735
108. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71. http://dx.doi.org/10.1136/annrheumdis-2011-201247
109. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomised, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. http://dx.doi.org/10.1002/art.21519
110. Quinn MA, Conaghan PG, O’Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35. http://dx.doi.org/10.1002/art.20712
111. O’Dell JR, Mikuls TR, Taylor T, Ahluwalia V, Brophy M, Warren S, et al. Rheumatoid arthritis comparison of active therapies in methotrexate suboptimal responders: validation of the strategy of conventional disease modifying anti-rheumatic drugs before biologicals. Arthritis Rheum 2012;64:S1297.
112. O’Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369:307-18. http://dx.doi.org/10.1056/NEJMoa1303006
113. Weinblatt ME, Fleischmann R, van Vollenhoven R, Emery P, Huizinga TWJ, Goldermann R, et al. Certolizumab pegol in patients with active rheumatoid arthritis aligned with NICE guidance for anti-TNF therapy: post-HOC analyses of the realistic phase IIIB randomised controlled study. Rheumatology 2012;51(Suppl. 3):abstract 200.
114. Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan AC, et al. A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open 2012;2:e001395. http://dx.doi.org/10.1136/bmjopen-2012-001395
115. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7. http://dx.doi.org/10.1136/ard.2006.068064
116. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-19. http://dx.doi.org/10.3109/s10165-008-0125-1
117. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti-tumour necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of star (safety trial of adalimumab in rheumatoid arthritis). J Rheumatol 2003;30:2563-71.
118. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomised, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86. http://dx.doi.org/10.1002/art.21734
119. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374:459-66. http://dx.doi.org/10.1016/S0140-6736(09)60944-2
120. Durez P, Malghem J, Toukap AN, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis: a randomised magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 2007;56:3919-27. http://dx.doi.org/10.1002/art.23055
121. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80. http://dx.doi.org/10.1002/art.23940
122. Van De Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, Van Riel PLCM, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16. http://dx.doi.org/10.1136/ard.2003.013052
123. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10(42) http://dx.doi.org/10.3310/hta10420
124. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9. http://dx.doi.org/10.1056/NEJM199901283400401
125. Wong M, Oakley SP, Young L, Jiang BY, Wierzbicki A, Panayi G, et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:1277-84. http://dx.doi.org/10.1136/ard.2007.086157
126. Zhang F-C, Hou Y, Huang F, Wu D-H, Bao C-D, Ni L-Q, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. Int J Rheum Dis 2006;9:127-30. http://dx.doi.org/10.1111/j.1479-8077.2006.00186.x
127. Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63:2854-64. http://dx.doi.org/10.1002/art.30463
128. Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol 2010;6:189-95. http://dx.doi.org/10.1586/eci.10.2
129. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Japanese Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate. Arthritis and Rheumatism Conference: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, October 2011, Chicago, IL, USA.
130. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland A-M, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomised placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21. http://dx.doi.org/10.1002/art.30158
131. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomised, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71. http://dx.doi.org/10.1002/art.21201
132. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. http://dx.doi.org/10.1016/S0140-6736(08)60453-5
133. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Meijide JAG, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19. http://dx.doi.org/10.1056/NEJMoa1112072
134. Kang Y, Park W, Park Y, Choe J, Bae S-C. Efficacy and safety of certolizumab pegol (CZP) with concomitant methotrexate (MTX) in Korean rheumatoid arthritis (RA) patients (PTS) with an inadequate response to MTX. Ann Rheum Dis 2012;71:666. http://dx.doi.org/10.1136/annrheumdis-2012-eular.501
135. Keystone E, van der Heijde D, Mason J, Landewe R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomised, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29. http://dx.doi.org/10.1002/art.23964
136. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804. http://dx.doi.org/10.1136/ard.2008.101659
137. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012;64:970-81. http://dx.doi.org/10.1002/art.33419
138. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four month phase III randomised radiographic study. Arthritis Rheum 2013;65:559-70. http://dx.doi.org/10.1002/art.37816
139. Bathon JM, Genovese MC. The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate. Clin Exp Rheumatol 2003;21:S195-7.
140. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol 2011;38:1585-92. http://dx.doi.org/10.3899/jrheum.110014
141. Scott DL, Ibrahim F, Farewell V, O’Keeffe AG, Ma M, Walker D, et al. Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: the TACIT trial. Health Technol Assess 2013;18(66). http://dx.doi.org/10.3310/hta18660
142. Smolen J, Fleischmann R, Guerette B. Adalimumab plus methotrexate vs. methotrexate monotherapy for early rheumatoid arthritis: 26-week results (first phase) from the 78-week optima study. Ann Rheum Dis 2010;69:102. http://dx.doi.org/10.1136/annrheumdis-2011-201247
143. Fleischmann R, Emery P. Long-term efficacy and safety of golimumab, a human anti-TNF alpha monoclonal antibody, in methotrexate-naïve rheumatoid arthritis patients: results from the go-before study. Ann Rheum Dis 2010;69:681.
144. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis. Arthritis Rheum 2013;65:28-38. http://dx.doi.org/10.1002/art.37711
145. AstraZeneca. A Randomised, Double-Blind (with Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients with Active Disease Receiving Background Methotrexate or Sulphasalazine. Clinical Study Report Synopsis. Drug substance AZD9056 hydrochloride. Study code D1520C00001. Edition 1; 2009. URL: www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/10775953 (accessed 8 August 2013).
146. Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602. http://dx.doi.org/10.1056/NEJM200011303432202
147. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379:1712-20. http://dx.doi.org/10.1016/S0140-6736(12)60027-0
148. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Ewals JA, Han KH, Hazes JM, et al. Patient-reported outcomes in a randomised trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum 2009;61:4-12. http://dx.doi.org/10.1002/art.24367
149. Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis 2001;60:817-27.
150. Peterfy C, Haraoui B, Durez P, Patra K, Kupper H. Decreased Incidence of Synovitis, Osteitis, and Erosion in Early RA Patients Treated with Adalimumab Plus Methotrexate Compared to Those With Methotrexate Alone: High-Field MRI Analysis from OPTIMA. Arthritis and Rheumatism Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting 10, Philadelphia, PA, 2010.
151. Ostergaard M, Emery P, Conaghan PG, Fleischmann R, Hsia EC, Xu W, et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis Rheum 2011;63:3712-22. http://dx.doi.org/10.1002/art.30592
152. Tocilizumab (RoActemra) for the Treatment of Rheumatoid Arthritis. Roche MTA Submission. 2013.
153. Conaghan PG, Emery P, Ostergaard M, Keystone EC, Genovese MC, Hsia EC, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 2011;70:1968-74. http://dx.doi.org/10.1136/ard.2010.146068
154. Emery P, Kavanaugh AF, Smolen J, Cifaldi MA, Chaves L, Guerette B, et al. Combination Therapy With Adalimumab Methotrexate Significantly Improved Work Ability, Physical Function, Fatigue, and Other Patient-Reported Outcomes in Early Rheumatoid Arthritis: Results From a 26-Week Analysis. Arthritis and Rheumatism Conference: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL, 2011.
155. Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomised multicenter study. J Rheumatol 2012;39:63-72. http://dx.doi.org/10.3899/jrheum.101161
156. Multiple Technology Appraisal. ID537. Certolizumab Pegol for the Treatment of Rheumatoid Arthritis that has Previously Been Treated with Conventional Disease-Modifying Anti-Rheumatic Drugs. UCB Pharma Submission. 2013.
157. Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware J, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002;8:231-40.
158. Allaart CF, Breedveld FC, Dijkmans BAC. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. J Rheumatol 2007;34:S25-33.
159. National Institute for Health and Care Excellence. Adalimumab, Etanercept, Infliximab, Certolizumab, Golimumab, Abatacept, and Tocilizumab for the Treatment of Rheumatoid Arthritis (Review of TA Guidance 130, 186, 224, 234, and Part Review of TA Guidance 225 and 247) [ID537]. Manufacturer submission of evidence: Infliximab (Remicade®). 2013.
160. Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003;48:1493-9. http://dx.doi.org/10.1002/art.11142
161. Graudal N, Jurgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomised placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010;62:2852-63. http://dx.doi.org/10.1002/art.27592
162. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010;7: CD008331. http://dx.doi.org/10.1002/14651858.cd008331
163. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010;1:CD008341. http://dx.doi.org/10.1002/14651858.cd008341
164. Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Galvez Munoz JG, Saiz Cuenca ES, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2011;2:CD007649. http://dx.doi.org/10.1002/14651858.cd007649.pub2
165. Singh JA, Wells GA, Christensen R, Tanjong GE, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;2:CD008794. http://dx.doi.org/10.1002/14651858.cd008794.pub2
166. Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002;3:CD003785. http://dx.doi. org/10.1002/14651858.cd003785
167. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005;3:CD005113. http://dx.doi.org/10.1002/14651858.cd005113.pub2
168. Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2003;4:CD004525. http://dx.doi. org/10.1002/14651858.cd004525
169. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;4:CD007848. http://dx.doi.org/10.1002/14651858.cd007848
170. Connock M, Tubeuf S, Malottki K, Uthman A, Round J, Bayliss S, et al. Certolizumab pegol (CIMZIA (R)) for the treatment of rheumatoid arthritis. Health Technol Assess 2010;14(Suppl. 2). http://dx.doi.org/10.3310/hta14suppl2/01
171. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 2011;15(14). http://dx.doi.org/10.3310/hta15140
172. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6(21). http://dx.doi.org/10.3310/hta6210
173. National Institute for Health and Care Excellence. Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for the Treatment of Rheumatoid Arthritis Not Previously Treated with Disease-Modifying Anti-Rheumatic Drugs and After the Failure of Conventional Disease-Modifying Anti-Rheumatic Drugs Only. Submission by AbbVie. 2013.
174. National Institute for Health and Care Excellence. Adalimumab, Etanercept, Infliximab, Certolizumab, Golimumab, Abatacept, and Tocilizumab for the Treatment of Rheumatoid Arthritis (Review of TA Guidance 130, 186, 224, 234, and Part Review of TA Guidance 225 and 247) [ID537]. Manufacturer submission of evidence: Golimumab (Simponi®). 2013.
175. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al. Effectiveness of tumour necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomised clinical trials. Arthritis Rheum 2006;54:3399-407. http://dx.doi.org/10.1002/art.22193
176. Pincus T, Sokka T. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis 2004;63:32-9. http://dx.doi.org/10.1136/ard.2004.028415
177. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. Oxford: Oxford University Press; 2005.
178. Bansback NJ, Brennan A, Ghatnekar O. Cost-effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002. http://dx.doi.org/10.1136/ard.2004.027565
179. Barbieri M, Wong JB, Drummond M. The cost-effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics 2005;23:2005. http://dx.doi.org/10.2165/00019053-200523060-00007
180. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8(11). http://dx.doi.org/10.3310/hta8110
181. Benucci M, Gobbi FL, Sabadini L, Saviola G, Baiardi P, Manfredi M. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of subcutaneous anti-TNF alpha treatment in Italian patients. Int J Immunopathol Pharmacol 2009;22:1147-52.
182. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62-72. http://dx.doi.org/10.1093/rheumatology/keg451
183. Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, et al. Modelling the cost-effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007;46:1345-54. http://dx.doi.org/10.1093/rheumatology/kem115
184. Chiou C-F, Choi J, Reyes CM. Cost-effectiveness analysis of biological treatments for rheumatoid arthritis. Expert Rev Pharmacoecon Outcomes Res 2004;4:307-15. http://dx.doi.org/10.1586/14737167.4.3.307
185. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002;29:1156-65.
186. Coyle D, Judd M, Blumenauer B, Cranney A, Maetzel A, Tugwell P, et al. Infliximab and Etanercept in Patients With Rheumatoid Arthritis: A Systematic Review and Economic Evaluation. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2006.
187. Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of sequential therapy with tumour necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol 2009;36:16-26. http://dx.doi.org/10.3899/jrheum.080257
188. Diamantopoulos A, Benucci M, Capri S, Berger W, Wintfeld N, Giuliani G, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ 2012;15:576-85. http://dx.doi.org/10.3111/13696998.2012.665110
189. Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents a cost-effectiveness analysis. Ann Intern Med 2009;151:612-21. http://dx.doi.org/10.7326/0003-4819-151-9-200911030-00006
190. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35. http://dx.doi.org/10.1093/rheumatology/keg107
191. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10. http://dx.doi.org/10.1136/ard.2003.010629
192. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost-effectiveness of etanercept (enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64:1174-9. http://dx.doi.org/10.1136/ard.2004.032789
193. Kobelt G, Lekander I, Lang A, Raffeiner B, Botsios C, Geborek P. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care 2011;27:193-200. http://dx.doi.org/10.1017/S0266462311000195
194. Lekander I, Borgstrom F, Svarvar P, Ljung T, Carli C, van Vollenhoven RF. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int J Technol Assess Health Care 2010;26:54-61. http://dx.doi.org/10.1017/S0266462309990596
195. Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, et al. Not all ‘quality-adjusted life-years’ are equal. J Clin Epidemiol 2007;60:616-24. http://dx.doi.org/10.1016/j.jclinepi.2006. 09.006
196. Nuijten MJC, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001;19:1051-64. http://dx.doi.org/10.2165/00019053-200119100-00006
197. Rubio-Terrés C, Dominguez-Gil A. Pharmacoeconomic analysis of the treatment of rheumatoid arthritis with leflunomide in comparison with the combination of infliximab and methotrexate. J Med Econ 2001;4:2001. http://dx.doi.org/10.3111/200104019034
198. Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ 2012;15:340-51. http://dx.doi.org/10.3111/13696998.2011.649327
199. Spalding JR, Hay J. Cost-effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006;24:1221-32. http://dx.doi.org/10.2165/00019053-200624120-00006
200. Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, et al. Modelling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol 2006;16:77-84. http://dx.doi.org/10.3109/s10165-006-0461-y
201. van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, de Vries-Bouwstra JK, Hazes JM, Kerstens PJ, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2009;61:291-9. http://dx.doi.org/10.1002/art.24169
202. Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology 2008;47:535-41. http://dx.doi.org/10.1093/rheumatology/ken007
203. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008;58:939-46. http://dx.doi.org/10.1002/art.23374
204. Welsing PMJ, Severens JL, Hartman M, Van Riel PLCM, Laan RFJM. Modelling the 5-year cost-effectiveness of treatment strategies including tumour necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 2004;51:964-73. http://dx.doi.org/10.1002/art.20843
205. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8. http://dx.doi.org/10.1016/S0002-9343(02) 01243-3
206. National Institute for Health and Care Excellence. The Clinical Effectiveness and Cost Effectiveness of Etanercept and Infliximab for Rheumatoid Arthritis and Juvenile Poly-Articular Idiopathic Arthritis (TA36). 2002. URL: www.nice.org.uk/guidance/ta36 (accessed 5 July 2013).
207. National Institute for Health and Care Excellence. Adalimumab, Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis. URL: www.nice.org.uk/guidance/ta130 (accessed 3 August 2013).
208. National Institute for Health and Care Excellence. Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for the Treatment of Rheumatoid Arthritis Not Previously Treated with Disease-Modifying Anti-Rheumatic Drugs and After the Failure of Conventional Disease-Modifying Anti-Rheumatic Drugs Only (Review of Technology Appraisal Guidance 130, 186, 224, 234 and a Part Review of Technology Appraisal Guidance 225 and 247). Bristol-Myers Squibb submission of evidence to NICE. 2013.
209. National Institute for Health and Care Excellence. Etanercept for the Treatment of Rheumatoid Arthritis. (Review of TA Guidance 130, 186, 224, 234 and Part Review of TA Guidance 225 and 247). Multiple Technology Appraisal (MTA). Pfizer submission. 2013.
210. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83. http://dx.doi.org/10.1136/bmj.313.7052.275
211. Eddy D. Technology Assessment: The Role of Mathematical Modelling. In Mosteller F, editor. Assessing Medical Technologies. Washington, DC: National Academy Press; 1985. pp. 144-60.
212. Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V, et al. Omeract 6 economics working group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003;30:886-90.
213. Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891-6.
214. Hyrich K, Symmons D, Watson K, Silman A, BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 2006;65:895-8. http://dx.doi.org/10.1136/ard.2005.043158
215. Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007;66:732-9. http://dx.doi.org/10.1136/ard.2006.066761
216. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 2009;68:789-96. [Erratum appears in Ann Rheum Dis 2011;70:238.] http://dx.doi.org/10.1136/ard.2008.099010
217. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29. http://dx.doi.org/10.1016/S0140-6736(12)61811-X
218. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11. http://dx.doi.org/10.1136/ard.2008.099291
219. Monthly Index of Medical Specialties. January 2013. URL: www.mims.co.uk (accessed 1 February 2013).
220. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2008. NICE Methods Guide 2008. URL: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed 20 July 2013).
221. Joint Formulary Committee. British National Formulary. 64 ed. London: BMJ Group and Pharmaceutical Press; 2012.
222. Joint Formulary Committee. British National Formulary (online). URL: www.medicinescomplete. com/mc/bnf/current/index.htm (accessed 1 April 2013).
223. Electronic Medicines Compendium. Tocilizumab Summary of Product Characteristics. 2011. URL: www.medicines.org.uk/EMC/browsedocuments.aspx (accessed February 2013).
224. NHS. National Schedule of Reference Costs Year: 2010-11 NHS Trusts and PCTS Combined HRG Data. 2013. URL: https://data.gov.uk/dataset/nhs-reference-costs-2010-11 (accessed 30 July 2013).
225. National Institute for Health and Care Excellence. Costing Template for Infliximab for the Treatment of Adults With Psoriasis (Guidance TA134). 2008. URL: www.nice.org.uk/guidance/ta134/resources (accessed 31 July 2013).
226. Bradford Teaching Hospitals NHS Trust. Shared Care Guidelines and Monitoring Protocols for Rheumatology Patients on Disease Modifying Drugs (Including Biologic Therapies). Bradford: Bradford Teaching Hospitals NHS Trust & Bradford and Airedale teaching Primary Care Trust; 2010.
227. National Institute for Health and Care Excellence. Costing Template: Tuberculosis: Clinical Diagnosis and Management of Tuberculosis and Measures for its Prevention and Control; Clinical Guideline 33. 2013. URL: www.nice.org.uk/guidance/cg117/resources (accessed 31 July 2013).
228. Curtis L. Unit Costs of Health and Social Care 2011. Canterbury: Personal Social Services Research Unit, University of Kent; 2011.
229. Chakravarty K, McDonald H, Pullar T, Taggart A, Chalmers R, Oliver S, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology 2008;47:924-5. http://dx.doi.org/10.1093/rheumatology/kel216a
230. Department of Health. NHS Trusts and PCTs Combined Reference Cost Schedules 2010-11. Department of Health; 2012. URL: https://data.gov.uk/dataset/nhs-reference-costs-2010-11/resource/91f6f5fd-c185-4bf0-8e56-718a4d769b24 (accessed 31 July 2013).
231. Roche. Achieving Clinical Excellence in the Treatment of Moderate to Severe Rheumatoid Arthritis. RoActemra® (Tocilizumab) NICE STA Submission. Manufacturer’s submission TA198. 2009.
232. Curtis L. Unit Costs of Health and Social Care 2012. Canterbury: Personal Social Services Research Unit, University of Kent; 2012.
233. Curtis L. Unit Costs of Health and Social Care 2010. Canterbury: Personal Social Services Research Unit, University of Kent; 2010.
234. Department of Health. NHS Reference Costs 2009-2010. 2011. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459 (accessed 1 April 2013).
235. Harland D, Gibbons C, Diamantopoulos A, Pang H, Huertas D, Dejonckheere F. Tocilizumab in patients where methotrexate is considered inappropriate-a cost-utility model for the UK. Value Health 2012;15:A277-575. http://dx.doi.org/10.1016/j.jval.2012.08.1403
236. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Klearman M, et al. Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial. Ann Rheum Dis 2012;71:S152. http://dx.doi.org/10.1136/annrheumdis-2012-eular.1963
237. UCB Pharma. Certolizumab Pegol (CIMZIA®) for the Treatment of Rheumatoid Arthritis. Manufacturer’s submission for TA186. 2009.
238. Schering-Plough Ltd. Golimumab for the Treatment of Rheumatoid Arthritis after Failure of Previous Disease-Modifying Antirheumatic Drugs. Manufacturer’s submission to NICE. 2010.
239. Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomised controlled radiate study. Rheumatology 2012;51:1860-9. http://dx.doi.org/10.1093/rheumatology/kes131
240. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21. http://dx.doi.org/10.1016/S0140-6736(09)60506-7
241. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Rheumatology 1997;36:551-9. http://dx.doi.org/10.1093/rheumatology/36.5.551
242. van der Heijde D, Landewe R, van Vollenhoven R, Fatenejad S, Klareskog L. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008;67:1267-70.http://dx.doi.org/10.1136/ard.2007.081331
243. Munro R, Hampson R, McEntegart A, Thompson E, Modhok R, Capell H. Improved functional outcome in patients with early RA treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998;57:88-93. http://dx.doi.org/10.1136/ard.57.2.88
244. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000;39:122-32. http://dx.doi.org/10.1093/rheumatology/39.2.122
245. Edwards CJ, Arden NK, Fisher D, Saperia JC, Reading I, van Staa TP, et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology2005;44:1394-8. http://dx.doi.org/10.1093/rheumatology/kei024
246. Hoyle M, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol 2011;11:139. http://dx.doi.org/10.1186/1471-2288-11-139
247. Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. http://dx.doi.org/10.1186/1745-6215-8-16
248. National Collaborating Centre for Chronic Conditions. National Clinical Guideline for Rheumatoid Arthritis. London: Royal College of Physicians; 2008.
249. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DPM, Hyrich KL. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9. http://dx.doi.org/10.1136/ard.2010.139774
250. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32. http://dx.doi.org/10.1002/art.27227
251. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumour necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8. http://dx.doi.org/10.1002/art.24463
252. Keystone EC, Cohen SB, Emery P, Kremer JM, Dougados M, Loveless JE, et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumour necrosis factor inhibitors: 5-year data from the REFLEX Study. J Rheumatol 2012;39:2238-46. http://dx.doi.org/10.3899/jrheum.120573
253. Smolen JS, Kay J, Landewe RBM, Matteson EL, Gaylis N, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebocontrolled GO-AFTER study through week 160. Ann Rheum Dis 2012;71:1671-9. http://dx.doi. org/10.1136/annrheumdis-2011-200956
254. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23. http://dx.doi.org/10.1136/ard.2008.092932
255. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974;19:732. http://dx.doi.org/10.1109/TAC.1974.1100705
256. Hjardem E, Ostergaard M, Podenphant J, Tarp U, Andersen LS, Bing J, et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumour necrosis factor alpha inhibitor? Ann Rheum Dis 2007;66:1184-9. http://dx.doi.org/10.1136/ard.2006.054742
257. Guyot P, Ades A, Ouwens M, Welton N. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012;12:9. http://dx.doi.org/10.1186/1471-2288-12-9
258. Trueman D, Livings C, Mildred M. PRM81 Methods of obtaining evidence from published survival data for use in decision analytic models. Value Health 2012;15:A475. http://dx.doi.org/10.1016/j.jval.2012.08.1544
259. Anderson J, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9. http://dx.doi.org/10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9
260. Wiles NJ, Symmons D. Resource Use Within the Norfolk Arthritis Register (NOAR) Cohort During the First Five Years of Disease. Report for Roche. London: NICE; 2005.
261. Department of Health. National Schedule of Reference Costs Year: 2010-11-NHS Trusts and PCTs Combined HRG Data. 2013. URL: www.gov.uk/government/publications/2010-11-referencecosts-publication (accessed 2 August 2013).
262. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modelling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002;46:2310-19. http://dx.doi.org/10.1002/art.10471
263. Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology 2000;39:603-11. http://dx.doi.org/10.1093/rheumatology/39.6.603
264. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56. http://dx.doi.org/10.1002/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P
265. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology 2005;44:1169-75. http://dx.doi.org/10.1093/rheumatology/keh703
266. Ducournau P, Keilhorn A, Wintfield N. Comparison of Linear and Non-Linear Utility Mapping Between HAQ and EQ-5D Using Pooled Data from the Tolicizumab Trials OPTION and LITHE. Poster 258; 2009.
267. Dolan P. Modelling Valuations for EuroQol Health States. Med Care 1997;35:1095-108. http://dx.doi.org/10.1097/00005650-199711000-00002
268. Russell AS, Conner-Spady B, Mintz A, Maksymowych WP. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol 2003;30:941-7.
269. Wolfe F, Hawley D. Measurement of the quality of life in rheumatic disorders using the EuroQol. Rheumatology 1997;36:786-93. http://dx.doi.org/10.1093/rheumatology/36.7.786
270. Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality-adjusted life-years by different preference-based instruments. Med Care 2003;41:791-801. http://dx.doi.org/10.1097/00005650-200307000-00003
271. Marra C, Woolcott J, Kopec J, Shojania K, Offer R, Brazier J. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ5D) and disease specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82. http://dx.doi. org/10.1016/j.socscimed.2004.08.034
272. Boggs R, Sengupta N, Ashraf T. Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab. Value Health 2002;5:452. http://dx.doi.org/10.1016/S1098-3015(10)61216-8
273. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisals. 2008. URL: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed 2 August 2013).
274. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisals. 2013. URL: www.nice.org.uk/article/pmg9/chapter/foreword (accessed 2 August 2013).
275. Bansback N, Marra C, Tsuchiya A, Anis A, Guh D, Hammond T, et al. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:963-71. http://dx.doi.org/10.1002/art.22885
276. Hernandez-Alava M, Wailoo AJ, Ara R. Tails from the Peak District: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health 2012;15:550-61. http://dx.doi.org/10.1016/j.jval.2011.12.014
277. Bansback N, Young A, Brennan A, Dixey J. A prognostic model for functional outcome in early rheumatoid arthritis. J Rheumatol 2006;33:1503-10.
278. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31. http://dx.doi.org/10.1093/rheumatology/keq242
279. Oppong R, Kaambwa B, Nuttall J, Hood K, Smith R, Coast J. The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries. Eur J Health Econ 2011:14:197-209. http://dx.doi. org/10.1007/s10198-011-0360-9
280. Dixon W, Symmons D, Lunt M, Watson K, Hyrich K, Silman A. Serious infection following anti-tumour necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904. http://dx.doi. org/10.1002/art.22808
281. Singh JA, Wells GA, Christensen R, Tanjong GE, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2012;2:CD008794. http://dx.doi.org/10.1136/annrheumdis-2012-eular.3407
282. Wolfe F, Mitchell D, Sibley J, Fries J, Bloch D, Williams C, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94. http://dx.doi.org/10.1002/art.1780370408
283. Office for National Statistics. Interim Life Tables: 2008-2010. URL: www.ons.gov.uk/ons/rel/lifetables/interim-life-tables/2008-2010/index.html (accessed 30 January 2013).
284. Lindgren P, Geborek P, Kobelt G. Modelling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care 2009;25:181-9. http://dx.doi.org/10.1017/S0266462309090230
285. Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, Rubbert-Roth A. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanerceptfailure. Eur J Health Econ 2010;11:95-104. http://dx.doi.org/10.1007/s10198-009-0205-y
286. Bristol-Myers Squibb. Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of Conventional Disease-Modifying Anti-Rheumatic Drugs. Manufacturer’s submission to NICE. 2010.
287. Wu B, Wilson A, Wang FF, Wang SL, Wallace DJ, Weisman MH, et al. Cost-effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in China. PLOS ONE 2012;7:e47373. http://dx.doi.org/10.1371/journal.pone.0047373
288. Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Rheum 2011;63:1142-9. http://dx.doi.org/10.1002/acr.20481
289. Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002;29:1851-7.
290. Office for National Statistics. Interim Life Tables, United Kingdom, 1980-82 to 2008-10. 2010. URL: www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-223324 (accessed 1 April 2013).
291. Deighton C, Hyrich K, Ding T, Ledingham J, Lunt M, Kiely P, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology 2010;49:1197-9. http://dx.doi.org/10.1093/rheumatology/keq006a
292. Norton S, Sacker A, Dixey D, Done J, Williams P, Young A. Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality. Rheumatology 2013;52:2016-24. http://dx.doi.org/10.1093/rheumatology/ket253
293. Norton S, Fu B, Verstappen S, Symmons D, Lunt M, Davies R, et al. Common Trajectories of HAQ Disability Progression Over 15-years in the Early Rheumatoid Arthritis Study and the Norfolk Arthritis Register. Poster. Berlin: EULAR; 2012.
294. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9. http://dx.doi.org/10.1016/S0140-6736(04)16676-2
295. Department of Health. NHS Reference Costs: Financial Year 2011 to 2012. URL: www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012 (accessed 1 April 2013).
296. Bollen K, Curran P. Autoregressive latent trajectory (ALT) models. A synthesis of two traditions. Sociol Method Res 2004;32:336-83. http://dx.doi.org/10.1177/0049124103260222
297. Satorra A, Bentler PM. A scaled difference chisquare test statistic for moment structure analysis. Psychometrika 2001;66:507-14. http://dx.doi.org/10.1007/BF02296192
298. Norton S, Verstappen SMM, Symmons DP, Lunt M, Davies R, Scott DL, et al. Common trajectories of HAQ disability progression over 15-years in the early rheumatoid arthritis study and the Norfolk arthritis register. Ann Rheum Dis 2012;71:S508. http://dx.doi.org/10.1136/annrheumdis-2012-eular.3060
299. Hernandez-Alava M, Wailoo A, Wolfe F, Michaud K. A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Med Decis Making 2013;34:919-30. http://dx.doi.org/10.1177/0272989X13500720
300. Plant MJ, O’Sullivan MM, Lewis PA, Camilleri JP, Coles EC, Jessop JD. What factors influence functional ability in patients with rheumatoid arthritis. Do they alter over time? Rheumatology 2005;44:1181-5. http://dx.doi.org/10.1093/rheumatology/keh707
301. Symmons D, Tricker K, Roberts C, Davies L, Dawes P, Scott D. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. Health Technol Assess 2005;9(34). http://dx.doi.org/10.3310/hta9340
302. McWilliams DF, Kiely P, Young A, Walsh D. Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort. BMC Musculoskelet Disord 2013;14:153. http://dx.doi.org/10.1186/1471-2474-14-153
303. Bansback N, Fu EHY, Sun H, Guh D, Zhang W, Lacaille D, et al. Impact of Biologics on Healthcare Utilisation in Patients with Rheumatoid Arthritis: An Instrumental Variable Approach. Canadian Rhuematology Meeting 2013. Poster presentation. CRA Annual Scientific Meeting and the AHPA Annual Meeting. Ottawa, Ontario, 13-16 February 2013.
304. Hernandez-Alava M, Wailoo A, Wolfe F, Michaud K. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology 2013;52:944-50. http://dx.doi.org/10.1093/rheumatology/kes400
305. Brazier JE, Yang YL, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010;11:215-25. http://dx.doi.org/10.1007/s10198-009-0168-z
306. Hawthorne G, Buchbinder R, Defina J. Functional Status and Health Related Quality of Life Assessment in Patients with Rheumatoid Arthritis (Working Paper 116). Melbourne, VIC; Monash University Centre for Health Program Evaluation; 2000.
307. Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriahc arthritis. Rheumatology 2006;45:1029-38. http://dx.doi.org/10.1093/rheumatology/kel147
308. Michaud K, Vera-Llonch M, Oster G. Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. J Rheumatol 2012;39:54-9. http://dx.doi.org/10.3899/jrheum.110491
309. O’Hagan A, Stevenson M, Madan J. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. Health Econ 2007;16:1009-23. http://dx.doi.org/10.1002/hec.1199
310. Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46. http://dx.doi.org/10.3899/jrheum.100208
311. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009;36:1429-41. http://dx.doi.org/10.3899/jrheum.081018
312. Haugeberg G, Conaghan PG, Quinn M, Emery P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2009;68:1898-1901. http://dx.doi.org/10.1136/ard.2008.106484
313. Bejarano V, Conaghan PG, Quinn MA, Saleem B, Emery P. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology 2010;49:1971-4. http://dx.doi.org/10.1093/rheumatology/keq194
314. Fleischmann R, Weinblatt ME, Schiff MH, Khanna D, Furst D, Maldonado MA. Changes in patient reported outcomes in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis: results from the ample (abatacept versus adalimumab comparison in biologic naive RA subjects with background methotrexate) trial. Arthritis Rheum 2012;64:S578.
315. Emery P, Smolen JS, Samborski W, Berenbaum F, Davies O, Ambrugeat J, et al. Efficacy and safety of certolizumab pegol after incomplete response to DMARDs in rheumatoid arthritis patients with low moderate disease activity: results from CERTAIN, a Phase IIIB study. Rheumatology 2012;51(Suppl. 3):Abstract 218.
316. Kameda H, Kurasawa T, Nagasawa H, Amano K, Takeuchi T. The addition of another disease-modifying anti-rheumatic drug, bucillamine, to methotrexate in place of infliximab improves the rate of infliximab-free sustained remission. Int J Rheum Dis 2010;13:107. http://dx.doi.org/10.3109/14397595.2013.844886
317. Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Kataharada K, Ishizuka T, et al. Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:431-7. http://dx.doi.org/10.1002/1529-0131 (199904)42:3<431::AID-ANR6>3.0.CO;2-2
318. Kremer JM, Westhovens R, Leon M, Di GE, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15. http://dx.doi.org/10.1056/NEJMoa035075
319. Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan A, et al. Randomized efficacy and discontinuation study of etanercept versus adalimumab (red sea): a pragmatic, open-label, non-inferiority study of first TNF inhibitor use in rheumatoid arthritis: 1-year data. Rheumatology 2012;51(Suppl. 3):Abstract 178.
320. Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol 2012;39:1185-91. http://dx.doi.org/10.3899/jrheum.111195
321. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50. http://dx.doi.org/10.1002/art.10308
322. Nishimoto N, Takagi N. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol 2010;20:539-47. http://dx.doi.org/10.3109/s10165-010-0328-0
323. van der Heide D. How to read radiographs according to the Sharp/van der Heijde method. Rheumatology 2000;27:261-3.
324. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with and methotrexate. Arthritis Rheum 2004;50:1051-65. http://dx.doi.org/10.1002/art.20159
325. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580-4. http://dx.doi.org/10.1136/ard.2008.092866